Company intelligence / Profile preview

Bachem

Bubendorf, Basel-Landschaft, Switzerlandbachem.com ↗

Ownership: Public · BANB
Employees: ~2200
Development stage: Commercial

Overview

Bachem is a global leader in the development and manufacture of peptides and oligonucleotides as active pharmaceutical ingredients. It serves pharmaceutical and biotech companies worldwide with products spanning research to commercial scale. The company does not have its own clinical pipeline but enables client programs across all stages.

Modalities: PeptidesOligonucleotidesSmall molecule APIs
Industry: Contract Manufacturing Organization

Partnerships

GlyTech Inc.

Financials

Market cap: $158.2K
Total revenue: $72.1K
Enterprise value: $2.9M

Beyond the preview

Go deeper on Bachem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bachem.

Explore the full profile